Lincoln Pharmaceuticals

₹513.70As of Sun 8 Nov 2026, 12:00 UTC

NSE:LINCOLNHealthcare

Country India

PE (Fwd) 10.29

TSR 10Y CAGR 8.60%

Div yield 0.35%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.52

PE TTM 11.71

TSR TTM (2.76%)

Mkt cap ₹10.43B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹570

10.87%

(19.88%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

6.710

Revenue₹B

—

4.721

5.103

5.805

6.232

6.710

7.175

9.19%

7.67

Revenue growth%

—

8.09

13.76

7.35

7.67

6.92

7.88

—

52.49

Gross margin%

—

52.99

51.84

51.24

52.34

52.49

52.45

52.34

12.53

Operating margin%

—

18.58

15.78

15.43

14.29

12.53

12.44

15.43

13.10

Net margin%

—

14.69

14.29

16.07

13.21

13.10

13.09

14.29

11.71

P/E ratio (avg)x

—

9.639

8.850

11.71

16.61

12.68

10.96

11.71

12.24

EV/EBITx

—

7.623

8.010

12.20

15.36

13.26

11.52

12.20

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

43.88

EPS₹

—

34.63

36.40

46.58

41.11

43.88

46.87

6.10%

—

6.74

EPS growth%

—

5.11

27.99

(11.74)

6.74

6.82

5.92

—

Bookvalue per sh₹

—

FCF per share₹

—

1.80

Dividend per sh₹

—

1.50

1.80

1.86

4.66%

—

0.35

Div yield (avg)%

—

0.45

0.47

0.33

0.26

0.32

0.36

0.33

4.10

Payout ratio%

—

4.33

4.12

3.86

4.38

4.10

3.97

4.12

20.03

Shares (diluted)M

—

20.03

◌20.03

—

Buyback yield%

—

◌—

—

D/E ratiox

—

10.29

Enterprise value₹B

—

6.685

6.452

10.93

13.68

11.15

10.29

13.63%

—

LT debt₹M

—

Peers (US$108.5M)

Cap (US$)

Bafna Pharmaceuticals…

114.5M

140.1x

Sigachi Industries…

112.1M

42.58x

Bajaj HealthCare…

111.5M

49.46x

Curatis Holding AG

109.2M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

201.2

94.67

Own earn%

—

Sh yield%

0.35

0.33

Owners

Insiders/Inst%

48.07

2.10

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

13–19

$1 testx

—

Incr. ROIC%

—

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹6.710B

9.19%

1.00×

Cost of revenue

₹3.188B

9.48%

1.01×

Operating expenses

₹2.681B

13.34%

1.16×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m